Pharmaceutical

Grifols prepares for late-stage plans with plasma-derived medicines in 2024

In an interview with Pharmaceutical Technology, the company’s chief scientific officer detailed the company’s upcoming 2024 plans.

Feb 28, 2024 - 18:00
Grifols prepares for late-stage plans with plasma-derived medicines in 2024
In an interview with Pharmaceutical Technology, the company’s chief scientific officer detailed the company’s upcoming 2024 plans.
Read the original article

Tags:

Previous Article

Minerva hit with FDA rejection for schizophrenia symptom drug

Next Article

Bristol Myers Squibb Expands Irish Campus with $400M Investment in Drug Manufact...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Amneal partners with mAbxience for denosumab biosimilars

Amneal partners with mAbxience for denosumab biosimilars

Oct 13, 2023

Lawmakers call on FDA to issue stricter bone graft guidance

Lawmakers call on FDA to issue stricter bone graft guid...

Aug 31, 2023

ITM raises $273 million to fund radionuclide therapy pipeline

ITM raises $273 million to fund radionuclide therapy pi...

Jun 5, 2023